These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33246974)

  • 21. PET/CT: Clinical role in lymphomas.
    Papathanasiou N
    Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV
    Fan Y; Zhang Y; Yang Z; Ying Z; Zhou N; Liu C; Song Y; Zhu J; Wang X
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28535082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. End-of-treatment
    Allioux F; Gandhi D; Vilque JP; Nganoa C; Gac AC; Aide N; Lasnon C
    Leuk Lymphoma; 2021 Dec; 62(12):2890-2898. PubMed ID: 34219589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Values of Different Evaluation Criteria of Interim
    Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].
    Wang RM; Li F; Liu CB; Guan ZW; Fu LP; Xu BX; Zhu HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):74-79. PubMed ID: 30738450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SUV
    Texte E; Lequesne J; Tilly H; Jardin F; Vera P; Stamatoullas A; Becker S
    Leuk Lymphoma; 2021 May; 62(5):1088-1097. PubMed ID: 33289431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.
    Baek DW; Cho HJ; Kim JH; Sohn SK; Song GY; Ahn SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Jeong SY; Hong CM; Min JJ; Moon JH; Yang DH
    In Vivo; 2020; 34(4):2127-2134. PubMed ID: 32606193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
    Eertink JJ; Burggraaff CN; Heymans MW; Dührsen U; Hüttmann A; Schmitz C; Müller S; Lugtenburg PJ; Barrington SF; Mikhaeel NG; Carr R; Czibor S; Györke T; Ceriani L; Zucca E; Hutchings M; Kostakoglu L; Loft A; Fanti S; Wiegers SE; Pieplenbosch S; Boellaard R; Hoekstra OS; Zijlstra JM; de Vet HCW
    Blood Adv; 2021 May; 5(9):2375-2384. PubMed ID: 33944897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
    Cheson BD; Kostakoglu L
    Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
    Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
    Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [
    Cohen D; Luttwak E; Beyar-Katz O; Hazut Krauthammer S; Bar-On Y; Amit O; Gold R; Perry C; Avivi I; Ram R; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):953-962. PubMed ID: 34480603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic role of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: a pilot study application of neural networks to predict time-to-event.
    Annunziata S; Pelliccioni A; Hohaus S; Maiolo E; Cuccaro A; Giordano A
    Ann Nucl Med; 2021 Jan; 35(1):102-110. PubMed ID: 33094420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
    Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
    [No Abstract]   [Full Text] [Related]  

  • 39. Are Semiquantitative Methods Superior to Deauville Scoring in the Monitoring Therapy Response for Pediatric Hodgkin Lymphoma?
    Ibrahim F; Gabelloni M; Faggioni L; Padma S; Visakh AR; Cioni D; Neri E
    J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
    Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
    Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.